- Home
- CMPO vs COGT Comparison
CMPO vs COGT Comparison
Compare CMPO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- COGT
- Stock Information
- Founded
- CMPO 2000
- COGT 2014
- Country
- CMPO United States
- COGT United States
- Employees
- CMPO N/A
- COGT N/A
- Industry
- CMPO Finance: Consumer Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- COGT Health Care
- Exchange
- CMPO Nasdaq
- COGT Nasdaq
- Market Cap
- CMPO 1.1B
- COGT 984.0M
- IPO Year
- CMPO N/A
- COGT 2018
- Fundamental
- Price
- CMPO $13.81
- COGT $8.90
- Analyst Decision
- CMPO Strong Buy
- COGT Buy
- Analyst Count
- CMPO 7
- COGT 6
- Target Price
- CMPO $15.79
- COGT $14.67
- AVG Volume (30 Days)
- CMPO 867.2K
- COGT 1.3M
- Earning Date
- CMPO 11-08-2024
- COGT 11-12-2024
- Dividend Yield
- CMPO N/A
- COGT N/A
- EPS Growth
- CMPO N/A
- COGT N/A
- EPS
- CMPO N/A
- COGT N/A
- Revenue
- CMPO $419,612,000.00
- COGT N/A
- Revenue This Year
- CMPO $11.13
- COGT N/A
- Revenue Next Year
- CMPO $8.04
- COGT N/A
- P/E Ratio
- CMPO N/A
- COGT N/A
- Revenue Growth
- CMPO 9.13
- COGT N/A
- 52 Week Low
- CMPO $4.61
- COGT $3.67
- 52 Week High
- CMPO $16.14
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CMPO 41.17
- COGT 28.97
- Support Level
- CMPO $12.50
- COGT $9.97
- Resistance Level
- CMPO $14.54
- COGT $11.16
- Average True Range (ATR)
- CMPO 0.70
- COGT 0.78
- MACD
- CMPO -0.24
- COGT -0.25
- Stochastic Oscillator
- CMPO 35.99
- COGT 2.02
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.